Textual/Methodological Inconsistencies in 'PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway' (DOI: 10.1186/s13046-019-1260-6)

Academic fraud report · Geng Detector

Summary

This report evaluates a 2019 paper published in Journal of Experimental & Clinical Cancer Research. The overall verdict is highly suspicious. The most serious concerns are textual cross-contamination from unrelated studies, indicating sloppy or template-driven writing. First, the Results section describing Fig. 3j refers to 'CRC cells' in a study exclusively using breast cancer cell lines (MCF-7, T47D). Second, the miRNA discussed throughout the paper is miR-20a, but one Results passage references 'miR-26a inhibitor', a molecule never introduced elsewhere. Third, a Western blot description (Fig. 7b) mentions HCT-8/5-FU, a colorectal cancer cell line, in a study on breast cancer and doxorubicin-resistant sublines. Image-level forensic analysis was not possible from the text-only input. Confidence in textual findings is high because the anomalies are direct textual contradictions; uncertainty remains regarding the integrity of the underlying experimental data, which requires access to raw blots and laboratory records.

Verdict

Highly suspicious. Multiple textual anomalies in a breast cancer study point to cross-disease template copy-pasting. Verdict on image/data integrity is pending review of original files.

Key findings

Cross-disease terminology intrusion (CRC cells): Page 7, Results section describing Fig. 3j (JC-1 staining), mentions "increased J-aggregates in CRC cells transfected with siPTENP1," although only breast cancer lines (MCF-7, T47D) are used in this study.
Molecule name swap (miR-20a vs. miR-26a): Page 8, Results describing Fig. 6c, references "miR-26a inhibitor" while the entire paper's axis is PTENP1/miR-20a/PTEN. No miR-26a is introduced or characterized elsewhere.
Foreign cell line (HCT-8/5-FU): Page 11, Results describing Fig. 7b, states co-transfection "in HCT-8/5-FU cells," a colorectal carcinoma line, in a study framed around breast cancer and doxorubicin-resistant sublines (MCF-7/ADR, T47D/ADR).
Image/data forensics not feasible: Text-only input precluded pixel-level review of Western blots (Fig. 2l, 3l, 5a/b, 6a/b, 7a/b/c) and other images; given textual anomalies, raw image integrity is flagged as high-risk pending inspection.

Evidence highlights

Direct quote (Page 7): "JC-1 staining also showed an increased J-aggregates in CRC cells transfected with siPTENP1 (Fig. 3j)." — CRC is undefined in this breast cancer study.
Direct quote (Page 8): "...lower in the cells transfected with miR-26a inhibitor than the control groups." — miR-26a is not a stated subject of this paper.
Direct quote (Page 11): "co-transfection of inmiR-20a and siPTENP1 in HCT-8/5-FU cells revealed a reversal effect..." — HCT-8/5-FU belongs to colorectal cancer research, not breast cancer.
DOI: 10.1186/s13046-019-1260-6

Notes

Author affiliation listed (per original report context): Dalian Medical University.
Confidence: high for the textual contradictions (verifiable from the published PDF); low for image-level manipulation claims until raw data are examined.
Recommended actions include: (1) posting the textual concerns on PubPeer; (2) requesting uncropped Western blots and flow cytometry FCS files from the corresponding author; (3) notifying the journal editorial office; (4) filing a research integrity complaint with the authors' institution.
Disclaimer: This report is AI-assisted and intended for academic discussion only; final determination of misconduct requires investigation by qualified institutions.